Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

Ulrik Lassen

doi:10.1016/S1470-2045(19)30789-2

Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

Afdeling for Kræftbehandling

9 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Lancet Oncology
Vol/bind	21
Udgave nummer	2
Sider (fra-til)	193-194
Antal sider	2
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(19)30789-2
Status	Udgivet - feb. 2020

Adgang til dokumentet

10.1016/S1470-2045(19)30789-2

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{ba2a0adeda994d37a15068b017aa5064,

title = "Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours",

keywords = "Benzamides, Carcinoma, Non-Small-Cell Lung, Humans, Indazoles, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins",

author = "Ulrik Lassen",

year = "2020",

month = feb,

doi = "10.1016/S1470-2045(19)30789-2",

language = "English",

volume = "21",

pages = "193--194",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

AU - Lassen, Ulrik

PY - 2020/2

Y1 - 2020/2

KW - Benzamides

KW - Carcinoma, Non-Small-Cell Lung

KW - Humans

KW - Indazoles

KW - Lung Neoplasms

KW - Protein-Tyrosine Kinases

KW - Proto-Oncogene Proteins

UR - http://www.scopus.com/inward/record.url?scp=85078478656&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30789-2

DO - 10.1016/S1470-2045(19)30789-2

M3 - Comment/debate

C2 - 31838008

SN - 1470-2045

VL - 21

SP - 193

EP - 194

JO - Lancet Oncology

JF - Lancet Oncology

IS - 2

ER -